763 related articles for article (PubMed ID: 27746366)
1. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
2. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
4. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
7. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway.
Xu H; Zhu J; Hu C; Song H; Li Y
J Physiol Biochem; 2016 Dec; 72(4):721-732. PubMed ID: 27534652
[TBL] [Abstract][Full Text] [Related]
9. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.
Wang DD; Li J; Sha HH; Chen X; Yang SJ; Shen HY; Zhong SL; Zhao JH; Tang JH
Gene; 2016 Sep; 590(1):44-50. PubMed ID: 27282281
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.
Yin Y; Wang X; Li T; Ren Q; Li L; Sun X; Zhang B; Wang X; Han H; He Y; Cao Z; Sun X; Zhou Z
Cancer Med; 2020 Feb; 9(4):1544-1552. PubMed ID: 31899608
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
[TBL] [Abstract][Full Text] [Related]
12. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.
Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J
Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
14. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
15. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
[TBL] [Abstract][Full Text] [Related]
17. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
[TBL] [Abstract][Full Text] [Related]
18. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway.
Gao X; Qin T; Mao J; Zhang J; Fan S; Lu Y; Sun Z; Zhang Q; Song B; Li L
J Exp Clin Cancer Res; 2019 Jun; 38(1):256. PubMed ID: 31196157
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
